Literature DB >> 34181882

What constitutes success in the roll-out of COVID-19 vaccines?

Maxwell J Smith1.   

Abstract

Entities:  

Year:  2021        PMID： 34181882     DOI： 10.1016/S0140-6736(21)01244-7

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  5 in total

1.  High-dose ivermectin for early treatment of COVID-19 (COVER study): a randomised, double-blind, multicentre, phase II, dose-finding, proof-of-concept clinical trial.

Authors:  Dora Buonfrate; Fabio Chesini; Davide Martini; Maria Carla Roncaglioni; Maria Luisa Ojeda Fernandez; Maria Francesca Alvisi; Irene De Simone; Eliana Rulli; Alessandro Nobili; Giacomo Casalini; Spinello Antinori; Marco Gobbi; Caterina Campoli; Michela Deiana; Elena Pomari; Gianluigi Lunardi; Roberto Tessari; Zeno Bisoffi
Journal:  Int J Antimicrob Agents       Date:  2022-01-06       Impact factor: 5.283

2.  One-week longitudinal daily description of moral distress, coping, and general health in healthcare workers during the first wave of the COVID-19 outbreak in Italy: A quantitative diary study.

Authors:  Duilio F Manara; Giulia Villa; Lisa Korelic; Cristina Arrigoni; Federica Dellafiore; Valentina Milani; Greta Ghizzardi; Arianna Magon; Noemi Giannetta; Rosario Caruso
Journal:  Acta Biomed       Date:  2021-10-05

3.  A study on willingness to take the COVID-19 vaccine at a tertiary institution community in Johannesburg, South Africa.

Authors:  Bhadrashil H Modi; Deidré Pretorius; Joel M Francis
Journal:  Afr J Prim Health Care Fam Med       Date:  2022-07-28

4.  Supply, then demand? Health expenditure, political leanings, cost obstacles to care, and vaccine hesitancy predict state-level COVID-19 vaccination rates.

Authors:  Joshua Teperowski Monrad; Sebastian Quaade; Timothy Powell-Jackson
Journal:  Vaccine       Date:  2022-09-08       Impact factor: 4.169

5.  Why we should not 'just use age' for COVID-19 vaccine prioritisation.

Authors:  Maxwell J Smith
Journal:  J Med Ethics       Date:  2021-07-09       Impact factor: 5.926
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.